Investments in technologies and capabilities are reaping rewards says Catalent which will continue placing “disproportionate emphasis” on its biologics business.
Sandoz has joined biosimilar developers calling on the US FDA to provide clear guidance on interchangability just a day after launching Zarxio, its Neupogen (filgrastim) copycat.